GTPases in Cancers: Therapeutic Opportunities and Challenges
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 762
Special Issue Editors
Interests: cancer biology; small molecule; inflammation; immunity; drug
Special Issue Information
Dear Colleagues,
GTPases are critical molecular switches in cell functions. GTPases play crucial roles in multiple cellular physiological processes, such as cell signaling, cell cycle regulation, and maintenance of cell polarity. Their abnormal activation or inactivation is closely associated with the occurrence and development of various diseases. Currently, GTPases are being investigated for their roles in malignancies, neurodegenerative diseases and cardiomyopathies. GTPases are considered difficult to target.
However, with the recent approval of KRAS inhibitors for treating pancreatic cancer and other high-risk malignancies, there is a renewed importance in re-examining GTPases to define their roles in diverse cancer states and to develop novel therapeutic agents. This re-evaluation is expected to unveil specific functions of GTPases in various cancer types, providing a foundation for designing more effective treatment strategies and opening up new avenues for developing innovative treatment targets and drugs. Since the recent approval of KRAS inhibitors for the treatment of pancreatic and other higher risk malignancies, GTPases deserve a revisit to define their roles in diverse disease states and novel develop therapeutic agents.
In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.
Dr. Rakesh K. K. Singh
Dr. Kyu Kwang Kim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GTAPses
- cancer
- Alzheimer’s disease
- pulmonary diseases
- cardiovascular diseases
- cell cycle
- proliferation
- secretion machinery and proteins
